Organometallic Ligands

Inhibits MET, VEGFR1-3, Tie and Ron tyrosine kinases; antineoplastic

(E)-2-Benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one is a synthetically derived organic compound, which serves as a selective inhibitor of specific protein kinases. It is synthesized through a series of organic reactions including condensation and amination, primarily in research laboratories focusing on medicinal chemistry. The mode of action involves the hindrance of kinase activity by binding to the enzyme's active site, thereby affecting intracellular signaling pathways. This type of targeted interference can lead to altered cell proliferation and apoptosis, and holds promise particularly in oncology research due to its potential to modulate cancer cell growth. Applications of (E)-2-Benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one are predominantly found in preclinical research stages, where it is utilized to investigate cellular mechanisms and potential therapeutic pathways. Through kinase inhibition, it is employed to understand disease processes and evaluate its feasibility as a lead compound in drug development projects.

?2-adrenergic receptor agonist; bronchodilator

Analeptic

5-(Azepan-2-ylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione is a synthetic chemical compound known for its role as a biochemical intermediate. This compound is synthesized through a controlled chemical process involving the reaction of relevant precursors under specific conditions, typically in a laboratory setting, making it an artificial construct rather than a naturally occurring substance. The mode of action of 5-(Azepan-2-ylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione involves its interaction with specific biological pathways, where it might act as an inhibitor or a modulator. Its unique structure allows it to engage in interactions that can influence various enzymatic functions, potentially interfering with or promoting certain biochemical processes. In terms of its uses and applications, this compound may serve as a tool in the development of pharmacological agents, offering a basis for the creation of molecules with potential therapeutic effects. It could be used in research settings to better understand biochemical pathways and disease mechanisms, providing insights that drive the innovation of novel treatments. Scientists explore its properties to leverage its potential across various fields of biochemical research.

Iptacopan is an oral, small-molecule therapeutic, which is a complement factor B inhibitor that targets the alternative pathway of the complement system. This pathway is a component of the immune system's innate response and, when dysregulated, can contribute to the pathogenesis of various complement-mediated diseases. The mode of action of Iptacopan involves the selective inhibition of complement factor B, a crucial protein in the alternative complement pathway. By precisely targeting this factor, Iptacopan effectively disrupts the formation of the C3 and C5 convertases, thereby reducing the downstream effects of complement activation, such as inflammation and cell lysis. Iptacopan is primarily used for the treatment of rare hematological conditions, such as paroxysmal nocturnal hemoglobinuria (PNH) and certain forms of atypical hemolytic uremic syndrome (aHUS). These disorders arise due to uncontrolled complement activation, leading to hemolysis and thrombosis. The inhibitor’s specific action makes it a promising candidate for efficiently addressing the underlying pathophysiology of these conditions. Ongoing research is evaluating its efficacy and safety across various complement-mediated diseases, aiming to define its full therapeutic potential within this domain.

FSL-1 is an advanced antimicrobial agent, which is derived from fatty acids and modified through a synthesis process involving surface-active molecules. This compound exhibits enhanced antimicrobial efficacy through its unique mode of action that disrupts microbial cell membranes by integrating into the lipid bilayer, causing structural instability and leakage of cellular contents. Such action effectively eliminates a broad spectrum of bacteria and fungi. The primary applications of FSL-1 are in the fields of biotechnology and pharmaceuticals, where it is utilized for sterilizing surfaces, equipment, and sometimes incorporated into formulations as a preservative. It is also finding increasing utilization in research laboratories for the purpose of maintaining sterile environments and in the development of novel antimicrobial treatments. Its efficacy and versatility make it an invaluable tool for scientists investigating microbial resistance and those engaged in the development of next-generation antimicrobial strategies.

HIF prolyl-hydroxylase inhibitor for treatment of anaemia

FTBMT is a GPR52 receptor agonist with an EC50 value of 71 nM. Studies demonstrate antipsychotic-like effects of FTBMT in murine models of schizophrenia. FTBMT elicits beneficial effects on cognitive processes such as spatial working memory and long-term memory in mice.

Competitive oxytocin receptor antagonist. Inhibits oxytocin-induced uterine contractions in vitro and in in vivo models of preterm labor.  Acts via Gαi signalling and activates NF-κB and MAPK pathways to elicit proinflammatory effects in the amnion.

IQ 1S is an advanced writing instrument, which is an innovation in sensor-integrated pens developed from cutting-edge optoelectronic engineering. With the integration of highly sensitive, miniaturized sensors and a sophisticated feedback system, IQ 1S provides users with real-time analysis and metadata collection while writing. This instrument utilizes a combination of pressure sensors and accelerometers to capture comprehensive writing data, including pressure, angle, and velocity. The product's primary application is in environments where precise writing analytics are critical, such as in ergonomic studies to assess handwriting characteristics, in educational tools to support handwriting improvement programs, and in research settings requiring detailed recording of writing dynamics. Furthermore, it can be indispensable in assistive technology development for individuals with fine motor skill challenges, ensuring that intervention strategies are effectively measured and optimized. The IQ 1S represents a significant advancement in integrating traditional writing instruments with modern data acquisition technology, offering a versatile tool for scientists and researchers focused on the intricate correlation between writing mechanics and cognitive processes.

Ent-ticagrelor is a chirally pure pharmaceutical compound, categorized as a P2Y12 receptor antagonist, derived synthetically. This stereoisomer exemplifies the principle of stereochemistry in drug development, focusing on molecular specificity. Its mode of action involves selective binding to the P2Y12 adenosine diphosphate (ADP) receptors on platelets. This binding effectively inhibits the ADP-mediated activation of the GPIIb/IIIa receptor complex, which is crucial for platelet aggregation and clot formation. Ent-ticagrelor is primarily utilized in the clinical management of acute coronary syndromes and in patients undergoing percutaneous coronary intervention (PCI) to prevent thrombotic cardiovascular events. By inhibiting platelet aggregation, it reduces the risk of adverse events such as myocardial infarction and stroke. The unique selectivity of this stereoisomer enhances its pharmacodynamic profile, potentially offering improved therapeutic outcomes with reduced side effects compared to its racemic counterpart.

AZD9833 is an oral selective estrogen receptor degrader (SERD), which is a small molecule therapeutic synthesized by AstraZeneca. Its mode of action involves binding to the estrogen receptor, leading to the receptor's conformational change and subsequent degradation. This mechanism significantly downregulates estrogen receptor signaling, which is a crucial pathway in the progression of estrogen receptor-positive breast cancers. AZD9833 is primarily used in the treatment of hormone receptor-positive breast cancer, particularly targeting patients who have developed resistance to prior endocrine therapies. The compound's oral bioavailability and potent activity position it as a promising candidate in the therapeutic landscape, potentially improving patient adherence and outcomes. Research has shown that AZD9833 effectively reduces tumor burden in preclinical models, and ongoing clinical trials aim to further validate its efficacy and safety. Given its innovative approach to targeting estrogen receptor degradation, AZD9833 represents a significant advance in endocrine therapy alternatives.

BAL-27862 is an investigational small molecule, which is a synthetic derivative developed through systematic medicinal chemistry approaches. It functions primarily as an inhibitor of microtubule polymerization, exhibiting a mode of action that targets cancer cell division by disrupting the mitotic spindle apparatus. As an anti-cancer agent, BAL-27862 interferes with the cellular processes essential for tumor growth and proliferation, thus demonstrating potential efficacy against various cancer types including those resistant to standard chemotherapies. In preclinical studies, BAL-27862 has shown promise in its ability to bypass multi-drug resistance mechanisms, making it a focus of interest for further clinical investigations. Its applications are primarily centered on oncology, where it holds potential for integration into therapeutic protocols aimed at treating malignancies that exhibit high levels of resilience against existing treatment modalities. The continued study of BAL-27862 could further elucidate its full potential and role in the development of advanced cancer therapeutics.

5-Chloro-2-methyl-3-isothiazolone-d3 is a deuterated form of the chemical compound 5-chloro-2-methyl-3-isothiazolone, often employed in specialized research settings. This compound is derived synthetically and isotopically labeled for accurate tracking in various analytical applications. The incorporation of deuterium atoms in place of hydrogen allows for enhanced detection and precise identification in mass spectrometry-based analyses. The primary mode of action for this labeled compound is its function as an internal standard in quantitative analytical methods. By facilitating the reliable quantification of its non-labeled counterpart, it helps in assessing the presence and concentration of the compound in complex matrices with increased accuracy. In scientific research, 5-Chloro-2-methyl-3-isothiazolone-d3 is predominantly used in studies focusing on the behavior and degradation of biocides in various environments. Its applications extend to quality control, where its presence ensures consistency and reliability in product formulations by enabling precise calibration of analytical instruments. Overall, it is an invaluable tool for chemists looking to achieve high degrees of specificity and accuracy in their experimental protocols.

Serine hydrolase inhibitor-11 is a biochemical research tool designed to target the serine hydrolase enzyme class. This compound is synthesized through advanced chemical methods, offering precise inhibitory effects on serine hydrolase enzymes. It functions by covalently binding to the active serine site within the enzyme's structure, effectively blocking its catalytic action and altering substrate metabolism. The primary utility of Serine hydrolase inhibitor-11 is in the field of biochemical and pharmacological research, where it is employed to study the enzymatic pathways involving serine hydrolases. These enzymes play critical roles in numerous physiological processes, making their modulation crucial for understanding pathological states and developing therapeutic strategies. Applications include elucidating the enzymatic mechanisms in various conditions, exploring drug discoveries, and investigating metabolic pathways. Its precise inhibition allows researchers to dissect complex biological interactions, providing insights into the enzyme's functional and structural roles within biological systems.

Mc-Gly-Gly-Phe is a synthetic tripeptide, which is commonly used in the field of peptide research. It consists of three amino acids: N-methylglycine (sarcosine), glycine, and phenylalanine. This peptide is typically derived through chemical synthesis, utilizing solid-phase peptide synthesis techniques to ensure precision and purity. The mode of action for Mc-Gly-Gly-Phe involves mimicking portions of larger, bioactive proteins or signaling molecules, providing a simplified model for studying protein interactions and functions. By replicating specific sequences, researchers can investigate the structural and functional attributes related to binding specificity, enzymatic activity, or receptor interaction. In terms of applications, Mc-Gly-Gly-Phe is employed extensively in biochemical assays, drug development studies, and structural analysis of peptides. It serves as a foundational tool for elucidating mechanisms of action for proteins and enzymes, allowing scientists to deconstruct and reconstruct biological processes at the molecular level. Additionally, it aids in the exploration of new therapeutic approaches by providing insights into peptide-based drug design and delivery systems.

Oltipraz metabolite M2 is a pharmacologically active compound, which is derived from the metabolism of Oltipraz, a well-known chemopreventive agent. This metabolite is produced through hepatic biotransformation processes and plays a critical role in mediating the biological effects associated with its parent compound. The mode of action of Oltipraz metabolite M2 involves modulation of specific cellular pathways, particularly the activation of the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway. This activation leads to the upregulation of genes responsible for the synthesis of detoxifying enzymes, contributing to its antioxidative and chemopreventive properties. Oltipraz metabolite M2 is primarily used in research settings to explore its potential in cancer prevention and treatment. Studies often focus on its ability to mitigate oxidative stress and influence carcinogen metabolism. This metabolite is of significant interest to scientists who are investigating new therapeutic strategies for reducing cancer risk and understanding the molecular mechanisms underlying chemopreventive actions.

DO34 analog is a biochemical compound, which is synthesized from organic sources to mimic specific biochemical pathways. Its mode of action involves selective modulation or inhibition of enzyme activity, allowing researchers to study various biological processes in vitro and in vivo. The compound is often utilized in fields such as biochemistry, pharmacology, and molecular biology for its ability to influence cellular mechanisms. The applications of DO34 analog are centered around understanding enzyme functions, investigating metabolic pathways, and exploring therapeutic targets for drug discovery. Researchers employ this analog to dissect complex biological interactions and assess potential intervention points for disease treatment. Through meticulous experimental design and comprehensive data analysis, scientists leverage the properties of DO34 analog to advance knowledge in life sciences and bolster the development of innovative medical solutions.

Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) that has been used to treat pain and inflammation. Ketoprofen inhibits the production of inflammatory prostaglandins, which are released by platelets in response to injury or infection. The main mechanism of action is inhibition of cyclooxygenase enzymes COX 1 and COX 2 at the level of transcriptional activation. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.